BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 38530235)

  • 1. Positive 18 F-FDG and Negative 68 Ga-FAPI-04 Findings in a Patient With Gallbladder Adenocarcinoma.
    Qi N; Chen X; Zhou Z; Yuan Z; Zhao J
    Clin Nucl Med; 2024 Jun; 49(6):540-542. PubMed ID: 38530235
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the diagnostic efficacy of
    Zhang Z; Jia G; Pan G; Cao K; Yang Q; Meng H; Yang J; Zhang L; Wang T; Cheng C; Zuo C
    Eur J Nucl Med Mol Imaging; 2022 Jul; 49(8):2877-2888. PubMed ID: 35243518
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Sahin E; Kus T; Aytekin A; Uzun E; Elboga U; Yilmaz L; Cayirli YB; Okuyan M; Cimen V; Cimen U
    J Nucl Med; 2024 Apr; 65(4):512-519. PubMed ID: 38485276
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Shangguan C; Yang C; Shi Z; Miao Y; Hai W; Shen Y; Qu Q; Li B; Mi J
    Int J Radiat Oncol Biol Phys; 2024 Jan; 118(1):285-294. PubMed ID: 37634891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparing the clinical value of baseline [
    Ding J; Qiu J; Hao Z; Huang H; Liu Q; Liu W; Ren C; Hacker M; Zhang T; Wu W; Li X; Huo L
    Eur J Nucl Med Mol Imaging; 2023 Nov; 50(13):4036-4050. PubMed ID: 37493664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of [
    Jiang D; Chen X; You Z; Wang H; Zhang X; Li X; Ren S; Huang Q; Hua F; Guan Y; Zhao J; Xie F
    Eur J Nucl Med Mol Imaging; 2022 Jan; 49(2):732-742. PubMed ID: 34297193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Head-to-Head Comparison of [
    Wegen S; van Heek L; Linde P; Claus K; Akuamoa-Boateng D; Baues C; Sharma SJ; Schomäcker K; Fischer T; Roth KS; Klußmann JP; Marnitz S; Drzezga A; Kobe C
    Mol Imaging Biol; 2022 Dec; 24(6):986-994. PubMed ID: 35771317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PET Imaging of Fibroblast Activation Protein in Various Types of Cancer Using
    Pang Y; Zhao L; Meng T; Xu W; Lin Q; Wu H; Zhang J; Chen X; Sun L; Chen H
    J Nucl Med; 2023 Mar; 64(3):386-394. PubMed ID: 36215571
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 68 Ga-FAPI-04 PET/CT for the Evaluation of Cholangiocarcinoma : Comparison With 18 F-FDG PET/CT and Abdominal 68 Ga-FAPI-04 PET/MR.
    Zhang Z; Cheng C; Jiang H; Pan G; Yu Y; Jin G; Zuo C
    Clin Nucl Med; 2024 May; 49(5):409-418. PubMed ID: 38465929
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Kessler L; Hirmas N; Pabst KM; Hamacher R; Ferdinandus J; Schaarschmidt BM; Milosevic A; Nader M; Umutlu L; Uhl W; Reinacher-Schick A; Lugnier C; Witte D; Niedergethmann M; Herrmann K; Fendler WP; Siveke JT
    J Nucl Med; 2023 Dec; 64(12):1910-1917. PubMed ID: 37973185
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of
    Pang Y; Zhao L; Luo Z; Hao B; Wu H; Lin Q; Sun L; Chen H
    Radiology; 2021 Feb; 298(2):393-402. PubMed ID: 33258746
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of 18 F-FDG PET/CT and 68 Ga-FAPI-04 PET/CT in patients with non-small cell lung cancer.
    Can C; Kepenek F; Kömek H; Gündoğan C; Kaplan İ; Taşdemir B; Güzel Y; Agüloğlu N; Karaoğlan H
    Nucl Med Commun; 2022 Oct; 43(10):1084-1091. PubMed ID: 35972340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The potential utility of [
    Lan L; Liu H; Wang Y; Deng J; Peng D; Feng Y; Wang L; Chen Y; Qiu L
    Eur J Nucl Med Mol Imaging; 2022 Feb; 49(3):963-979. PubMed ID: 34410435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Head-to-head comparison of [
    Ballal S; Yadav MP; Roesch F; Satapathy S; Moon ES; Martin M; Wakade N; Sheokand P; Tripathi M; Chandekar KR; Agarwal S; Sahoo RK; Rastogi S; Bal C
    Eur J Nucl Med Mol Imaging; 2023 Dec; 51(1):233-244. PubMed ID: 37642703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A head-to-head comparison of
    Qin C; Liu F; Huang J; Ruan W; Liu Q; Gai Y; Hu F; Jiang D; Hu Y; Yang K; Lan X
    Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3228-3237. PubMed ID: 33609152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparisons of Quantitative Parameters of Ga-68-Labelled Fibroblast Activating Protein Inhibitor (FAPI) PET/CT and [
    Siripongsatian D; Promteangtrong C; Kunawudhi A; Kiatkittikul P; Boonkawin N; Chinnanthachai C; Jantarato A; Chotipanich C
    Mol Imaging Biol; 2022 Oct; 24(5):818-829. PubMed ID: 35486293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Head to head comparison of
    Gao C; Liu H; Zhou L; Huang W; Liu X
    Hell J Nucl Med; 2024; 27(1):35-45. PubMed ID: 38629816
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imaging fibroblast activation protein in liver cancer: a single-center post hoc retrospective analysis to compare [
    Guo W; Pang Y; Yao L; Zhao L; Fan C; Ke J; Guo P; Hao B; Fu H; Xie C; Lin Q; Wu H; Sun L; Chen H
    Eur J Nucl Med Mol Imaging; 2021 May; 48(5):1604-1617. PubMed ID: 33179149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fibroblast Activation Protein-Targeted PET/CT with
    Luo Y; Pan Q; Yang H; Peng L; Zhang W; Li F
    J Nucl Med; 2021 Feb; 62(2):266-271. PubMed ID: 32513902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual-tracer PET/CT protocol with [
    Wegen S; Weindler J; Voltin CA; van Heek L; Schomäcker K; Fischer T; Marnitz S; Kobe C; Drzezga A; Roth KS
    Strahlenther Onkol; 2024 Jan; 200(1):28-38. PubMed ID: 37584717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.